Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines

Oncology Letters

Volumn 8, Issue 4, 2014, Pages 1739-1744

  Gu, Mengli ^a   Zhang, Yan ^a   Zhou, Xinxin ^a   Ma, Han ^a   Yao, Hangping ^a   Ji, Feng ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Antineoplastic therapy; Extracellular signal regulated protein kinase 1 2; Gastric cancer; Proton pump inhibitors; Rabeprazole

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY ASSAY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PH; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; WESTERN BLOTTING;

EID: 84919433647     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2354     Document Type: Article

References (30)

1. Fais S: Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med 267: 515-525, 2010.
2. Rabon EC and Reuben MA: The mechanism and structure of the gastric H, K-ATPase. Annu Rev Physiol 52: 321-344, 1990.
3. Sachs G, Shin JM and Howden CW: Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 23 (Suppl 2): 2-8, 2006.
4. Shin JM, Cho YM and Sachs G: Chemistry of covalent inhibition of the gastric (H +, K +)-ATPase by proton pump inhibitors. J Am Chem Soc 126: 7800-7811, 2004.
5. Roche VF: The chemically elegant proton pump inhibitors. Am J Pharm Educ 70: 101, 2006.
6. Pantoflickova D, Dorta G, Ravic M, Jornod P and Blum AL: Acid inhibition on the first day of dosing: comparison of four proton pump inhibitors. Aliment Pharmacol Ther 17: 1507-1514, 2003.
7. Besancon M, Simon A, Sachs G and Shin JM: Sites of reaction of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 272: 22438-22 4 4 6, 1997.
8. Stubbs M, McSheehy PM and Griffiths JR: Causes and consequences of acidic pH in tumors: a magnetic resonance study. Adv Enzyme Regul 39: 13-30, 1999.
9. Stubbs M, Rodrigues L, Howe FA, et al: Metabolic consequences of a reversed pH gradient in rat tumors. Cancer Res 54: 4011-4016, 1994.
10. Holm E, Hagmüller E, Staedt U, et al: Substrate balances across colonic carcinomas in humans. Cancer Res 55: 1373-1378, 1995.
11. Vaupel P, Kallinowski F and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49: 6449-6465, 1989.
12. Tannock IF and Rotin D: Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 49: 4373-4384, 1989.
13. Helmlinger G, Yuan F, Dellian M and Jain RK: Interstitial pH and pO2gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 3: 177-182, 1997.
14. Yeo M, Kim DK, Kim YB, et al: Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 10: 8687-8696, 2004.
15. Ke Y, Ning T and Wang B: Establishment and characterization of a SV40 transformed human fetal gastric epithelial cell line-GES-1. Zhonghua Zhong Liu Za Zhi 16: 7-10, 1994 (In Chinese).
16. Pérez-Sayáns M, García-García A, Reboiras-López MD and Gándara-Vila P: Role of V-ATPases in solid tumors: importance of the subunit C (Review). Int J Oncol 34: 1513-1520, 2009.
17. Pérez-Sayáns M, Somoza-Martín JM, Barros-Ang ueir a F, Rey JM and García-García A: V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev 35: 707-713, 2009.
18. Trédan O, Galmarini CM, Patel K and Tannock IF: Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441-1454, 2007.
19. De Milito A and Fais S: Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 1: 779-786, 2005.
20. Mullin JM, Gabello M, Murray LJ, et al: Proton pump inhibitors: actions and reactions. Drug Discov Today 14: 647-660, 2009.
21. Fais S, De Milito A, You H and Qin W: Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 67: 10627-10 63 0, 2007.
22. Kromer W, Krüger U, Huber R, Hartmann M and Steinijans VW: Differences in pH-dependent activation rates of substituted benzimidazoles and biological in vitro correlates. Pharmacology 56: 57-70, 1998.
23. Kirchheiner J, Glatt S, Fuhr U, et al: Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 65: 19-31, 2009.
24. Marelli S and Pace F: Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroenterol Hepatol 6: 423-435, 2012.
25. De Milito A, Marino ML and Fais S: A rationale for the use of proton pump inhibitors as antineoplastic agents. Curr Pharm Des 18: 1395-1406, 2012.
26. Nishi T and Forgac M: The vacuolar (H+)-ATPases-nature's most versatile proton pumps. Nat Rev Mol Cell Biol 3: 94-103, 2002.
27. Hinton A, Bond S and Forgac M: V-ATPase functions in normal and disease processes. Pflugers Arch 457: 589-598, 2009.
28. Sennoune SR, Luo D and Martínez-Zaguilán R: Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem Biophys 40: 185-206, 2004.
29. Kim EK and Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405, 2010.
30. Ballif BA and Blenis J: Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 12: 397-408, 2001.